<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489903</url>
  </required_header>
  <id_info>
    <org_study_id>RRx001-211-01</org_study_id>
    <nct_id>NCT02489903</nct_id>
  </id_info>
  <brief_title>RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)</brief_title>
  <official_title>A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EpicentRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EpicentRx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize
      small cell and non-small cell lung cancer, ovarian cancer and high grade neuroendocrine tumor
      patients who previously responded and now have failed a platinum based doublet to the
      previously effective therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, four-arm, three stage, pilot study for co-administration of RRx-001
      with autologous blood once weekly until progression followed by reintroduction of
      platinum-based doublet therapy.

      The study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize
      patients who previously responded and now have failed a platinum based doublet.

      In the first stage of the study three (3) subjects with SCLC, NSCLC, ovarian cancer and HGNEC
      in each arm will receive RRx-001 until progression or intolerable toxicity at which point a
      platinum doublet therapy will be introduced or reintroduced. The first three patients will
      enrolled for safety and assessment for unacceptable toxicity. Each cohort will initially
      enroll 3 patients to assess for safety. If one of the 3 patients enrolled has an unexpected
      Adverse Events, then this combination would be considered unacceptable and the cohort would
      be stopped. If no unexpected AE occur then additional patients will be enrolled, a total of
      10 patients per cohort. Each cohort will undergo a temporary pause after 10 patients are
      enrolled to assess safety and efficacy. If greater than 1/3 of patients (4 patients) have
      unexpected AE, then this cohort will be stopped for unacceptable toxicities. If at the
      completion enrollment of 10 subjects, at least 1 will need to have stable disease or better.
      If any arm has 1/10 subjects that has stable disease or better, then additional patients
      would be enrolled in this arm. Total patients that can be enrolled are 31 patients with
      NSCLC, 26 patients with SCLC, 26 patients with High Grade Neuroendocrine and 26 with Ovarian
      Cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability of platinum doublet therapy post RRx-001</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the level of serum biomarkers will be calculated and treatment samples will be compared to baseline samples using one-sample tests (e.g., paired t test or Wilcoxon signed rank test).</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>Small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive RRx-001 until progression or intolerable toxicity followed by cisplatin/carboplatin plus etoposide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive RRx-001 until progression or intolerable toxicity followed by cisplatin/carboplatin plus albumin (nab-paclitaxel or Abraxane)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuroendocrine tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive RRx-001 until progression or intolerable toxicity followed by cisplatin/carboplatin plus etoposide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovarian epithelial cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive RRx-001 until progression or intolerable toxicity followed by carboplatin/paclitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RRx-001</intervention_name>
    <arm_group_label>Small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Non Small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Neuroendocrine tumors</arm_group_label>
    <arm_group_label>Ovarian epithelial cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin/carboplatin plus albumin (nab-paclitaxel or Abraxane)</intervention_name>
    <description>To be dosed after RRx-001</description>
    <arm_group_label>Non Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin/carboplatin plus etoposide</intervention_name>
    <description>To be dosed after RRx-001</description>
    <arm_group_label>Small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Neuroendocrine tumors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin/paclitaxel.</intervention_name>
    <description>To be dosed after RRx-001</description>
    <arm_group_label>Ovarian epithelial cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have histologically or cytologically confirmed advanced or metastatic
             Resistant/Refractory Small Cell Lung Cancer (SCLC), EGFR TKI Resistant EGFR+ T790M
             Negative Non-Small Cell Lung Cancer (NSCLC), Resistant/Refractory Epithelial Ovarian
             Cancer (EOC) or High-Grade Neuroendocrine Carcinoma (HGNEC)

          -  Must have previously received a platinum or platinum doublet based regimen for
             advanced/metastatic disease or have platinum refractory disease defined as relapse
             within 6 months.

          -  Life expectancy of â‰¥ 12 weeks

          -  ECOG performance status 0-2

          -  Adequate organ and marrow function both prior to administration of RRx-001 and prior
             to administration of platinum doublet based regimen

          -  Prior chemoembolization, radiofrequency ablation, or radiation is allowed as long as
             the patient has measurable disease and the disease that is being measured is at least
             12 weeks out from palliative therapy

          -  Women of child-bearing potential and men with partners of child-bearing potential must
             agree to use adequate contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry, for the duration of study participation, and for 90
             days following completion of therapy.

        Exclusion Criteria:

          -  Symptomatic central nervous system metastasis

          -  History of needing to permanently discontinue prior platinum doublet-based regimen for
             reasons other than progression (i.e. toxicity)

          -  History of more than 3 prior rounds platinum doublet based regimens.

          -  History of an allergic reaction to previous received platinum-doublet, or history of
             having to discontinue previous exposed chemotherapy secondary to a toxicity to
             previous chemotherapy. Known severe hypersensitivity to etoposide, nab-paclitaxel,
             pemetrexed, cisplatin, or carboplatin

          -  Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, congestive
             heart failure, myocardial infarction within 6 months of study, chronic renal disease,
             chronic pulmonary disease or active uncontrolled infection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Oronsky, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>EpicentRx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meaghan Stirn</last_name>
    <phone>8588122069</phone>
    <email>mstirn@epicentrx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Caroen</last_name>
    <phone>8588122069</phone>
    <email>scaroen@epicentrx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie San Pedro-Salcedo</last_name>
      <phone>650-724-1388</phone>
      <email>msanpedro@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Sukhmani Padda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Cancer Center</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Jordan</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>3287</phone_ext>
      <email>jessica.jordan@va.gov</email>
    </contact>
    <investigator>
      <last_name>Michal Rose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amie Lake</last_name>
      <phone>574-647-6784</phone>
      <email>ALake@beaconhealthsystem.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary Jane Danner</last_name>
      <phone>574-647-7309</phone>
      <email>MDanner@beaconhealthsystem.org</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas J Reid, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Cason</last_name>
      <phone>859-260-3197</phone>
      <email>stephanie.cason@bhsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Micheal F Stephens</last_name>
      <phone>859-260-6456</phone>
      <email>micheal.stephens@BHSI.com</email>
    </contact_backup>
    <investigator>
      <last_name>Arvinda Padmanabhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja Skeete</last_name>
      <phone>301-319-4599</phone>
      <email>sonja.t.skeete.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Karen Zeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Allegiance Health</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Strzalkowski, RN</last_name>
      <phone>517-205-1522</phone>
      <email>KSTRZAL1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Peterson, RN OCN</last_name>
      <phone>(517) 205-1549</phone>
      <email>npeters8@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Malcolm Trimble, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Blume</last_name>
      <phone>314-362-0872</phone>
      <email>dan.blume@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Morgensztern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Hendricks</last_name>
      <phone>513-584-5725</phone>
      <email>hendrilu@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>John C Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Choquette, MSN, RN</last_name>
      <phone>703-208-9268</phone>
      <email>Karin.Choquette@USONCOLOGY.COM</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Ross, RN</last_name>
      <phone>304-581-1158</phone>
      <email>cjross@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epigenetics</keyword>
  <keyword>resensitization</keyword>
  <keyword>Platinum doublets</keyword>
  <keyword>lung cancer</keyword>
  <keyword>Ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

